Department of Anesthesiology, Chongqing University Cancer Hospital, Chongqing, People's Republic of China.
School of Medicine, Chongqing University, Chongqing, People's Republic of China.
Clin Interv Aging. 2024 Feb 9;19:219-227. doi: 10.2147/CIA.S440902. eCollection 2024.
Noradrenaline (NA) is commonly used intraoperatively to prevent fluid overload and maintain hemodynamic stability. Clinical studies provided inconsistent results concerning the effect of NA on postoperative outcomes. As aging is accompanied with various diseases and has the high possibility of the risk for postoperative complications, we hypothesized that intraoperative NA infusion in older adult patients undergoing major non-cardiac surgeries might potentially exert adverse outcomes.
In this retrospective propensity score-matched cohort study, older adult patients undergoing major non-cardiac surgeries were selected, 1837 receiving NA infusion during surgery, and 1072 not receiving NA. The propensity score matching was conducted with a 1:1 ratio and 1072 patients were included in each group. The primary outcomes were postoperative in-hospital mortality and complications.
Intraoperative NA administration reduced postoperative urinary tract infection (OR:0.124, 95% CI:0.016-0.995), and had no effect on other postoperative complications and mortality, it reduced intraoperative crystalloid infusion (OR:0.999, 95% CI:0.999-0.999), blood loss (OR: 0.998, 95% CI: 0.998-0.999), transfusion (OR:0.327, 95% CI: 0.218-0.490), but increased intraoperative lactate production (OR:1.354, 95% CI:1.051-1.744), and hospital stay (OR:1.019, 95% CI:1.008-1.029).
Intraoperative noradrenaline administration reduces postoperative urinary tract infection, and does not increase other postoperative complications and mortality, and can be safely used in older adult patients undergoing major non-cardiac surgeries.
去甲肾上腺素(NA)常用于术中预防液体超负荷和维持血流动力学稳定。临床研究对于 NA 对术后结局的影响结果不一致。由于衰老伴随着各种疾病,并且术后并发症的风险很高,我们假设在接受非心脏大手术的老年患者术中输注去甲肾上腺素可能会产生不良结局。
在这项回顾性倾向评分匹配队列研究中,选择了接受非心脏大手术的老年患者,术中输注去甲肾上腺素的患者有 1837 例,未输注去甲肾上腺素的患者有 1072 例。采用 1:1 比例进行倾向评分匹配,每组纳入 1072 例患者。主要结局是术后院内死亡率和并发症。
术中去甲肾上腺素给药减少了术后尿路感染(OR:0.124,95%CI:0.016-0.995),对其他术后并发症和死亡率无影响,减少了术中晶体液输注(OR:0.999,95%CI:0.999-0.999)、出血量(OR:0.998,95%CI:0.998-0.999)、输血(OR:0.327,95%CI:0.218-0.490),但增加了术中乳酸生成(OR:1.354,95%CI:1.051-1.744)和住院时间(OR:1.019,95%CI:1.008-1.029)。
术中去甲肾上腺素给药可减少术后尿路感染,不会增加其他术后并发症和死亡率,可安全用于接受非心脏大手术的老年患者。